NCT01642056View on ClinicalTrials.gov

EPI-743 for Metabolism or Mitochondrial Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2012

Primary Completion Date

September 24, 2019

Study Completion Date

September 24, 2019

Conditions
Mitochondrial DiseaseNeurologyMyopathy
Interventions
DRUG

EPI-743

This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.

DRUG

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Human Genome Research Institute (NHGRI)

NIH

NCT01642056 - EPI-743 for Metabolism or Mitochondrial Disorders | Biotech Hunter | Biotech Hunter